Esperion Therapeutics has reached a settlement with Aurobindo Pharma, preventing Aurobindo from marketing generic versions of NEXLETOL and NEXLIZET in the US before April 19, 2040. This agreement resolves ongoing patent litigation related to Aurobindo's attempts to gain approval for generic versions of these cholesterol-lowering drugs. Litigation continues against other companies seeking to market generics earlier, with uncertain outcomes. The settlement helps Esperion protect its market exclusivity for these cardiovascular therapies for over a decade.
Esperion's settlement with Aurobindo Pharma is the story's subject, with Pluang market data providing context. As of Nov 10, 2026 19:42 WIB, 83 of 150 Health-sector US stocks rose while 55 fell. Notable movers include WGS at USD 56.50 (-14.03%, 0% Sell / 100% Buy), BKD at USD 10.30 (+10.63%, 100% Sell / 0% Buy), and LQDA at USD 49.97 (+4.39%, 97% Sell / 3% Buy).
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
